Trade Now

Capital at risk Advertisement
Share Name Share Symbol Market Type Share ISIN Share Description
Premaitha LSE:NIPT London Ordinary Share GB00BN31ZD89 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 9.10 9.00 9.20 0.00 01:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Software & Computer Services 6.1 -9.5 3.0 3.0 38

Yourgene Health PLC ISO 15189:2012 accreditation received

01/09/2021 7:00am

RNS Non-Regulatory


TIDMYGEN

Yourgene Health PLC

01 September 2021

`Yourgene Health plc

("Yourgene" or the "Group" or the "Company")

Yourgene Genomic Services receive ISO 15189:2012 accreditation

Validating its COVID-19 testing and sequencing services, providing assurance of compliance to international standards to deliver quality levels of performance and competence

Manchester, UK - 1 September 2021: Yourgene (AIM: YGEN), the international molecular diagnostics group, announces that following assessments by the UK accreditation service (UKAS), it has received ISO 15189:2012 accreditation for its COVID-19 testing and sequencing services, providing assurance that the Company's

Citylabs 1.0 laboratory in Manchester,   meets internationally recognised gold standards. 

Assessments under UKAS ensure that laboratories meet the relevant requirements including the operation of a quality management system and the ability to demonstrate that specific activities are performed within the criteria set out in the relevant standard . This achievement sets a solid foundation for Yourgene, enabling the Company to have certificates and reports accepted in over 80 countries around the world. ISO 15189:2012 accreditation provides confidence that Yourgene's medical laboratories deliver quality levels of performance and competence and confirms that the Company is operating a clinical service that is safe, reliable and consistent conveying trust to stakeholders and decision-makers and allows for a more rigorous system in operation.

Lyn Rees, CEO of Yourgene commented: "We are so pleased to have been accredited with this ISO standard as it serves to recognise the quality levels of performance at our Citylab 1.0 laboratory. Being a globally recognised accreditation opens up over 80 countries to Yourgene aiding our global operation."

 
Yourgene Health plc                                                    Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                                investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Singer Capital Markets (Joint Corporate                                Tel: +44 (0)20 7496 3000 
 Broker) 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                                  Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
Walbrook PR Ltd (Media and Investor         Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Lianne Cawthorne                         Mob: 07980 541 893 / Mob: 07584 391 303 
 
 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down's Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABRGDIGUXDGBB

(END) Dow Jones Newswires

September 01, 2021 02:00 ET (06:00 GMT)

1 Year Premaitha Chart

1 Year Premaitha Chart

1 Month Premaitha Chart

1 Month Premaitha Chart
ADVFN Advertorial
Your Recent History
LSE
NIPT
Premaitha
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20221006 04:34:09